Roxanne Strachan
Overview
Explore the profile of Roxanne Strachan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
155
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Doumit M, Strachan R, Lazarus R, Middleton P, Dentice R, Marouvo J, et al.
Health Serv Insights
. 2023 Oct;
16:11786329231205145.
PMID: 37854074
Background: Standard of care recommend that patients with cystic fibrosis (CF) require screening investigations to assess for complications. Changing models of care due to the COVID19 pandemic may have impacted...
2.
Homaira N, Strachan R, Quinn H, Beggs S, Bhuiyan M, Bowen A, et al.
Vaccine
. 2023 Aug;
41(42):6401-6402.
PMID: 37625991
No abstract available.
3.
Homaira N, Strachan R, Quinn H, Beggs S, Bhuiyan M, Bowen A, et al.
Vaccine
. 2022 Nov;
41(1):85-91.
PMID: 36400662
Background: We aimed to assess the direct protective effect of 13 valent pneumococcal conjugate vaccine (13vPCV) against invasive pneumococcal pneumonia (IPP; including pneumonia and empyema) in children using a nation-wide...
4.
Strachan R, Homaira N, Beggs S, Bhuiyan M, Gilbert G, Lambert S, et al.
Thorax
. 2021 Jan;
76(5):487-493.
PMID: 33504566
Background: Empyema is a serious complication of pneumonia frequently caused by (SP). We assessed the impact of the 13-valent pneumococcal conjugate vaccine (13vPCV) on childhood pneumonia and empyema after inclusion...
5.
Garg M, Leach S, Pang T, Needham B, Coffey M, Katz T, et al.
J Cyst Fibros
. 2017 Jul;
17(1):109-113.
PMID: 28754328
Background: The pathogenesis of gut inflammation, bacterial dysbiosis and increased rates of malignancy in CF is unclear. Fecal M2-pyruvate kinase (M2-PK) is a biomarker indicative of cellular proliferation that may...
6.
Saddi V, Beggs S, Bennetts B, Harrison J, Hime N, Kapur N, et al.
Orphanet J Rare Dis
. 2017 Jul;
12(1):133.
PMID: 28743279
Background: Childhood interstitial lung disease (chILD) represents a rare heterogeneous group of respiratory disorders. In the absence of randomized controlled clinical trials, global collaborations have utilized case series with an...
7.
Garg M, Leach S, Coffey M, Katz T, Strachan R, Pang T, et al.
J Cyst Fibros
. 2017 Apr;
16(5):631-636.
PMID: 28416415
Background: Fecal calprotectin may be used as a non-invasive method to assess the effect of novel therapies on the gut in cystic fibrosis (CF). Method: Stools from CF patients and...
8.
Stelzer-Braid S, Tovey E, Willenborg C, Toelle B, Ampon R, Garden F, et al.
J Med Virol
. 2015 Sep;
88(4):578-87.
PMID: 26331908
Much of what is known about the seasonality of human rhinovirus (hRV) infections has been learned from the study of acute asthma exacerbations presenting to emergency care, including those among...
9.
Dhaliwal J, Leach S, Katz T, Nahidi L, Pang T, Lee J, et al.
J Pediatr Gastroenterol Nutr
. 2014 Dec;
60(4):521-6.
PMID: 25539196
Objective: The aim of the study was to evaluate and compare faecal markers of intestinal inflammation in children with cystic fibrosis (CF), and determine whether intestinal inflammation adversely affects the...
10.
Tovey E, Stelzer-Braid S, Toelle B, Oliver B, Reddel H, Willenborg C, et al.
J Allergy Clin Immunol
. 2014 Dec;
135(3):663-9.e12.
PMID: 25476729
Background: Viruses are frequently associated with acute exacerbations of asthma, but the extent to which they contribute to the level of day-to-day symptom control is less clear. Objective: We sought...